Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
about
The role of oxidative stress in Parkinson's diseaseInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyNovel therapeutic approaches in multiple system atrophyChanges in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure.Drug development for rare mitochondrial disordersPathogenesis-targeted, disease-modifying therapies in Parkinson disease.Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.Animal models of Parkinson's disease: a gateway to therapeutics?Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review.The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease.Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature.Mitochondrial control of cell bioenergetics in Parkinson's disease.The MPTP Story.Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.Assessing the accuracy and reproducibility of computer-assisted analysis of (123) I-FP-CIT SPECT using BasGan (V2).1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.Rasagiline prevents cyclosporine A-sensitive superoxide flashes induced by PK11195, the initial signal of mitochondrial membrane permeabilization and apoptosis.Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
P2860
Q24307946-F6A9A19E-2868-45D5-9396-0717677962BFQ28069609-C3EEE4B2-4FC0-4C46-B744-ED98470DD74BQ34696470-E402587E-DC16-465D-A83F-9F1F45ADF43FQ35172603-52F4E4C7-DA58-4567-A097-FA28615675C5Q36762826-BD5A1496-E4A2-4DFD-B0D5-974CDA6A23FBQ37506492-B1A0ED43-3C4C-4A1E-927B-E340A6AB1517Q37996077-32BCA97D-2B3A-4030-BFBB-0CBE0208E150Q38155480-F3E33F3F-A433-4FF1-8782-251EF933EB5DQ38156172-2B2EE9CF-7980-4298-93E1-A5059A64D38EQ38202314-5879C620-CE88-4B6F-969B-58DFA68DD233Q38246682-2DF887BB-74D2-44CA-A3BA-722D7D2EAEF0Q38497529-D0935100-070F-4260-B053-A97057564EFCQ38811534-43007DBA-684E-4E73-AE7D-9212ED759A4AQ41825283-2718B176-5F2E-407C-8D67-256AA6BE6B19Q43442012-684E4791-9E42-4F86-8142-6517BFFB9359Q45709602-742A7722-6EDE-4780-A284-FCDBCA91D927Q48108548-98999CBC-5843-4180-BDB3-E36032E8A383Q53159866-697B343C-A2C2-4BF7-B02E-8906922EE9C7Q54099574-49F66C86-EF0D-474C-A613-59A42C9CA6BB
P2860
Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Explaining ADAGIO: a critical ...... linical effects of rasagiline.
@en
Explaining ADAGIO: a critical ...... linical effects of rasagiline.
@nl
type
label
Explaining ADAGIO: a critical ...... linical effects of rasagiline.
@en
Explaining ADAGIO: a critical ...... linical effects of rasagiline.
@nl
prefLabel
Explaining ADAGIO: a critical ...... linical effects of rasagiline.
@en
Explaining ADAGIO: a critical ...... linical effects of rasagiline.
@nl
P2860
P356
P1433
P1476
Explaining ADAGIO: a critical ...... linical effects of rasagiline.
@en
P2093
J William Langston
Peter Jenner
P2860
P304
P356
10.1002/MDS.23926
P407
P577
2011-09-23T00:00:00Z